万泰生物：预计2025年度净利润为-4.1亿元到-3.3亿元

Group 1 - The company expects a net profit attributable to shareholders of the parent company to be between -4.1 billion and -3.3 billion yuan for the year 2025, indicating a loss compared to the same period last year [1] - The decline in performance is primarily due to the vaccine sector, which is under pressure from domestic vaccine procurement policies, industry competition, and consumer hesitancy, leading to significant decreases in both revenue and profit [1] - The company faces severe challenges on both the revenue and production fronts, particularly with its bivalent HPV vaccine, which is adversely affected by the market presence of Merck's nine-valent HPV vaccine, substantial government procurement price cuts, and insufficient consumer demand [1] Group 2 - The company is actively addressing the adverse effects of the bivalent HPV vaccine by exploring international markets and accelerating the research and development of innovative products, achieving some success [1] - In the international market, the revenue from the bivalent HPV vaccine is expected to experience exponential growth by 2025, while the first innovative product, the nine-valent HPV vaccine, has successfully launched domestically [1] - As of the end of the reporting period, the nine-valent HPV vaccine has completed market access in 27 provinces and is rapidly expanding coverage across over 30,000 points of vaccination, aiming to increase vaccination rates [1]